Clinical trial
Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Cystic Fibrosis
NCT02456103 is registered in ClinicalTrials.gov with PTC Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Cystic Fibrosis
- Lead sponsor
- PTC Therapeutics
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- August 31, 2015
- Completion date
- June 2, 2017
- Enrollment
- 246 (actual)
- Sites
- 70
Conditions
As the registry lists them; a condition with its own page is linked.